"10.1371_journal.pone.0029198","plos one","2012-02-22T00:00:00Z","Tine Glendorf; Louise Knudsen; Carsten E Stidsen; Bo F Hansen; Anne Charlotte Hegelund; Anders R SÃ¸rensen; Erica Nishimura; Thomas Kjeldsen","Diabetes Research Unit, Novo Nordisk A/S, Maaloev, Denmark; Diabetes Research Unit, Novo Nordisk A/S, Gentofte, Denmark","Conceived and designed the experiments: TG TK ARS EN. Performed the experiments: TG LK ACH. Analyzed the data: TG LK ACH ARS CES TK. Wrote the paper: TG. Revised the manuscript for important intellectual content: BFH.","All authors are employed by Novo Nordisk A/S and hold shares in Novo Nordisk A/S. This does not alter the authors's adherence to all the PLoS ONE policies on sharing data and materials. There are two patents relating to material pertinent to this article: 1. New fast-acting insulin analogs comprise specific amino acid substitutions or deletions in the human B-chain, useful for reducing blood glucose levels in mammals to treat type 1 diabetes, type 2 diabetes, and hyperglycemia. Patent Number: WO2009021955-A1; EP2178909-A1; CN101778862-A; JP2010535841-W; US2011021423-A1. Patent Assignee: NOVO NORDISK A/S Inventor(s): BALSCHMIDT P; GLENDORF T; HAVELUND S; et al. 2. New fast-acting insulin analogs comprise specific amino acid substitutions or deletions in human B-chain, useful for preparing compositions for reducing blood glucose levels and treating diabetes and hyperglycemia. Patent Number: WO2009021956-A2; WO2009021956-A3; EP2178911-A2; CN101796071-A; JP2010535842-W. Patent Assignee: NOVO NORDISK A/S. Inventor(s): BALSCHMIDT P; GLENDORF T; HAVELUND S; et al. There are no products in development or modified products based on these patents or relating to the manuscript.","2012","02","Tine Glendorf","TG",8,TRUE,4,3,6,1,TRUE,TRUE,FALSE,0,NA,FALSE
